The immunomodulation therapy developer has been backed by Pablo Legorreta in the wake of a phase 2 trial of its therapy for organ transplant patients.
ITBMed, a Sweden-based immunomodulation therapy developer with ties to Columbia and Harvard universities, has closed a round sized at up to $67m led by private investor Pablo Legorreta.
ITBMed is researching immunomodulatory drugs for organ transplant patients to improve their quality of life and reduce the likelihood of long-term complications.
The company’s lead asset is a drug called Siplizumab that has been shown to mitigate the need for immunosuppression, a means used to constrain the transplant recipient’s immune system so that…
